李为春, 崔林, 陈珏, 朱银喜, 潘家华, 李丽, 沈艺, 张志勇. 晚期非小细胞肺癌多西紫杉醇节拍化疗的临床研究[J]. 中国肿瘤临床, 2012, 39(13): 932-935. DOI: 10.3969/j.issn.1000-8179.2012.13.014
引用本文: 李为春, 崔林, 陈珏, 朱银喜, 潘家华, 李丽, 沈艺, 张志勇. 晚期非小细胞肺癌多西紫杉醇节拍化疗的临床研究[J]. 中国肿瘤临床, 2012, 39(13): 932-935. DOI: 10.3969/j.issn.1000-8179.2012.13.014
shu
Weichun LI, Lin CUI, Jue CHEN, Yinxi ZHU, Jiahua PAN, Li LI, Yi SHEN, Zhiyong ZHANG. Clinical Study of Metronomic Chemotharapy with Paclitaxel for Advanced Non-small-cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(13): 932-935. DOI: 10.3969/j.issn.1000-8179.2012.13.014
Citation: Weichun LI, Lin CUI, Jue CHEN, Yinxi ZHU, Jiahua PAN, Li LI, Yi SHEN, Zhiyong ZHANG. Clinical Study of Metronomic Chemotharapy with Paclitaxel for Advanced Non-small-cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(13): 932-935. DOI: 10.3969/j.issn.1000-8179.2012.13.014
shu

晚期非小细胞肺癌多西紫杉醇节拍化疗的临床研究

Clinical Study of Metronomic Chemotharapy with Paclitaxel for Advanced Non-small-cell Lung Cancer

    摘要
  • 摘要:
      目的  回顾性分析低剂量多西紫杉醇节拍化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效、不良反应, 以及对非小细胞肺癌患者血清血管内皮细胞生长因子浓度的影响。
      方法  收集2009年9月至2010年9月姜堰市人民医院呼吸科住院治疗的44例NSCLC患者, 随机数分组法将入选患者分为治疗组和对照组, 治疗组采用多西紫杉醇25mg/m2, 每周给药1次, 连用3周为1周期。对照组多西紫杉醇75mg/m2第1天, 21天为1周期; 顺铂30mg/m2, 第1~3天, 21天为1周期。化疗两周期后按RECIST标准评价疗效, 依据NCI-CTC3.0行不良反应评价。采用酶联免疫吸附法(ELISA)检测两组患者化疗前后血清VEGF浓度。
      结果  1例患者失访。治疗组和对照组RR(CR+PR)分别为35%、30.4%, 两组PFS分别为4.40个月、4.62个月; 1年OSR分别为30%、30.43%;两组疗效比较无统计学差异(P > 0.05)。两组主要不良反应为恶性呕吐, 白细胞下降及疲乏, 治疗组不良反应发生率显著低于对照组(P < 0.05)。两组化疗后血清VEGF浓度均有下降, 但治疗组治疗前后血清VEGF差值较对照组更为明显(P < 0.01)。
      结论  低剂量多西紫杉醇节拍化疗方案治疗晚期非小细胞肺癌是一种安全有效的方案, 可显著降低患者血清VEGF, 推断具有抑制肿瘤新生血管形成的作用, 值得临床进一步研究。

     

    Abstract:
      Objective  To retrospect the efficacy and salty, as well as the effect on the serum vasculer endothelial growth factor (VEGF) level, of metronomic chemotherapy with lowdose paclitaxel in the treatment of patients with advanced non-small-cell lung cancer.
      Methods  From July 2009 to September 2010, 44 patients were randomized into two arms: paclitaxel 25mg/m2 intravenous infusion (Ⅳ) on days1、8 and 15 every three weeks (treatment group), and paclitaxel 75mg/m2 Ⅳ on daysl plus platinum Ⅳ on daysl~3 every three weeks (the control group); the efficacy and safety were evaluated accoeding to RECIST and NCI-CTC3.0 after two cycles, the serum VEGF level were detected using Enzyme-linked immunosorbent assay(ELISA) around the treatment.
      Results  One patient was un-contacted.Response rate were 35% VS 30.4%, progressive-free survival were 4.4 VS 4.62, and overal survial rate of one year were 30% VS 30.43% in treatment group and the control group respectively; There is no statistically significant difference between both groups (P > 0.05). The main side effect were Leukopenia, Nausea/vomiting and Diarrhea, the control group were obviously (P < 0.05). The serum VEGF level were decreased after treatment with the treatment group were significant.
      Conclusion  Metronomic low-dose paclitaxel in treating advanced NSCLC is effective and can be well tolerated, through the probable mechanism of decreasing serum VEGF level to inhibit tumor angiogenesis. It is worthy of further clinical stydy.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回